🇺🇸 FDA
Patent

US 8003629

21-substituted progesterone derivatives as new antiprogestational agents

granted A61PA61P15/00A61P15/04

Quick answer

US patent 8003629 (21-substituted progesterone derivatives as new antiprogestational agents) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Aug 18 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Aug 23 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 18 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
34
CPC classes
A61P, A61P15/00, A61P15/04, A61P15/08, A61P5/24